Teads Holding $TEAD

Recent News (4)

• Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma PR Newswire · 26 Aug 2026 Craig Gibbs, PhD, MBA, appointed President and Chief Executive Officer Ellen Lubman, MBA, joins as Chief Business and Strategy Officer Oncology veteran Tim Clackson, PhD, appointed to the Board of Dir…
• Teads Files Lawsuit Against Google Seeking Financial Damages Following Federal Court Antitrust Ruling GlobeNewswire · 03 Aug 2026 NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teads Holding Co. (Nasdaq: TEAD), the omnichannel outcomes platform, today announced that it has filed a lawsuit in the U.S. District Court for the Southe…
• Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma PR Newswire · 29 Jul 2026 FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the clinical potential in advanced mesothelioma. ISM633…
• Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors PR Newswire · 27 Jul 2026 Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway Global Phase 1 multicenter study evaluates safety, tolerability, and pre…